Published in Ann Rheum Dis on November 19, 2008
Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol (2010) 4.21
Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum (2011) 2.14
Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther (2009) 1.98
Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs (2010) 1.89
The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs (2010) 1.86
Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol (2013) 1.68
Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis. Arthritis Res Ther (2009) 1.58
Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self Nonself (2010) 1.45
Adverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitis. PLoS One (2015) 1.41
Engineering the variable region of therapeutic IgG antibodies. MAbs (2011) 1.33
Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol (2013) 1.10
Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study). Ann Rheum Dis (2011) 1.08
Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol (2011) 1.04
Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. Immunotherapy (2012) 1.04
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol (2015) 1.00
The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther (2010) 0.98
Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine. Mediators Inflamm (2014) 0.96
IgG4 production against adalimumab during long term treatment of RA patients. J Clin Immunol (2012) 0.96
Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies. J Biol Chem (2014) 0.90
Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment. Arthritis Rheumatol (2014) 0.88
Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study. Arthritis Res Ther (2010) 0.87
The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients. Arthritis Res Ther (2013) 0.87
Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). Clin Rheumatol (2011) 0.86
P-glycoprotein and drug resistance in systemic autoimmune diseases. Int J Mol Sci (2014) 0.86
A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis (2015) 0.86
Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab. Clin Rheumatol (2010) 0.85
Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients. Arthritis Care Res (Hoboken) (2015) 0.85
Protection from articular damage by passive or active anti-tumour necrosis factor (TNF)-α immunotherapy in human TNF-α transgenic mice depends on anti-TNF-α antibody levels. Clin Exp Immunol (2013) 0.84
Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity. MAbs (2015) 0.84
Subcutaneous abatacept for the treatment of rheumatoid arthritis. Rheumatology (Oxford) (2013) 0.84
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. BMC Musculoskelet Disord (2012) 0.84
Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes. Front Immunol (2016) 0.83
Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol (2015) 0.82
Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis (2010) 0.82
A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 2-model applications. CPT Pharmacometrics Syst Pharmacol (2014) 0.81
Biologic concentration testing in inflammatory bowel disease. Inflamm Bowel Dis (2015) 0.81
Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. Mol Ther Methods Clin Dev (2016) 0.80
Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. Arthritis Res Ther (2016) 0.80
The human G1m1 allotype associates with CD4+ T-cell responsiveness to a highly conserved IgG1 constant region peptide and confers an asparaginyl endopeptidase cleavage site. Genes Immun (2011) 0.80
The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis. Br J Clin Pharmacol (2013) 0.79
Infliximab in the treatment of rheumatoid arthritis. Biologics (2009) 0.79
Pharmacokinetics of adalimumab in Crohn's disease. Eur J Clin Pharmacol (2015) 0.79
Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis model. Arthritis Res Ther (2012) 0.79
Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease. World J Gastroenterol (2012) 0.79
Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study. Arthritis (2015) 0.77
Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study. Arthritis Res Ther (2015) 0.77
Immunogenicity of Anti-TNF-α Biotherapies: II. Clinical Relevance of Methods Used for Anti-Drug Antibody Detection. Front Immunol (2015) 0.77
Practical application of acid dissociation in monitoring patients treated with adalimumab. Rheumatol Int (2014) 0.76
No Correlations Between the Development of Specific IgA and IgM Antibodies Against Anti-TNF Blocking Agents, Disease Activity and Adverse Side Reactions in Patients with Rheumatoid Arthritis. Open Rheumatol J (2013) 0.76
Effect of Anti-TNF Antibodies on Clinical Response in Rheumatoid Arthritis Patients: A Meta-Analysis. Biomed Res Int (2016) 0.75
Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study. PLoS One (2016) 0.75
Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis. PLoS One (2015) 0.75
Silicone Oil Microdroplets Can Induce Antibody Responses Against Recombinant Murine Growth Hormone in Mice. J Pharm Sci (2016) 0.75
Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis. Expert Opin Drug Metab Toxicol (2016) 0.75
New pharmacological strategies in rheumatic diseases. J Med Life (2016) 0.75
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications. J Immunol Res (2016) 0.75
Infliximab-Induced Hypothyroidism: A Novel Case and Postulations concerning the Mechanism. Case Rep Med (2013) 0.75
Long-term use of adalimumab in the treatment of rheumatic diseases. Open Access Rheumatol (2009) 0.75
Is there potential for Therapeutic Drug Monitoring of Biologic Agents in Rheumatoid Arthritis? Br J Clin Pharmacol (2016) 0.75
Cholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to Fab 2 fragments. PLoS One (2013) 0.75
Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence. BMJ Open (2016) 0.75
Infliximab therapy efficacy and persistence at a Canadian academic centre despite a change in access procedure. Clin Rheumatol (2011) 0.75
Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab. Cytokine (2017) 0.75
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. RMD Open (2017) 0.75
[Biomarkers and personalized medicine]. Z Rheumatol (2013) 0.75
[Switching within the active ingredient group or changing the mechanism of action. Data situation by failure of the first line biologic]. Z Rheumatol (2015) 0.75
Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors. Front Immunol (2017) 0.75
Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay. PLoS One (2017) 0.75
The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what's in it for African and Middle Eastern rheumatologists. Clin Rheumatol (2012) 0.75
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis (2004) 3.64
The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol (2005) 3.59
Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science (1986) 2.83
Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis (2004) 2.65
Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis (2004) 2.25
Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment Pharmacol Ther (2013) 2.21
Mediators of immunity: lymphokines and monokines. Adv Immunol (1980) 1.99
Autoantibodies to cytokines--friends or foes? Immunol Today (1990) 1.98
Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia (2002) 1.93
Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis (2005) 1.93
Development of quality indicators for monitoring of the disease course in rheumatoid arthritis. Ann Rheum Dis (2009) 1.79
Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity. J Immunol (1987) 1.74
The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet (2009) 1.73
The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. Rheumatology (Oxford) (2004) 1.72
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2011) 1.70
The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis (2007) 1.66
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis (2003) 1.64
Effectiveness, side-effects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study. Br J Dermatol (2009) 1.59
Comment on the use of self-reporting instruments to assess patients with rheumatoid arthritis: the longitudinal association between the DAS28 and the VAS general health. Arthritis Rheum (2006) 1.59
Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. Rheumatology (Oxford) (2006) 1.57
Cyclosporin for polymyositis. Lancet (1984) 1.55
Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis (2004) 1.54
Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) (2007) 1.53
Interleukin-1 beta-induced nitric oxide production in isolated rat pancreatic islets requires gene transcription and may lead to inhibition of the Krebs cycle enzyme aconitase. Endocrinology (1991) 1.52
Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. Pediatr Pulmonol (1993) 1.51
Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors. Ann Rheum Dis (2007) 1.51
Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect Immun (1993) 1.50
Treatment of chronic endogenous uveitis with fusidic acid. Lancet (1991) 1.50
Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol (1999) 1.50
Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. J Clin Invest (1994) 1.48
Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist. Nat Biotechnol (1997) 1.47
A new homeobox-leucine zipper gene from Arabidopsis thaliana. Plant Mol Biol (1992) 1.44
Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis (2003) 1.44
Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. Mult Scler (2008) 1.42
Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia (1986) 1.42
Immunohistological detection of interleukin I-like molecules and tumour necrosis factor in human epidermis before and after UVB-irradiation in vivo. Br J Dermatol (1988) 1.41
Decreased prolactin response to hypoglycaemia in patients with rheumatoid arthritis: correlation with disease activity. Ann Rheum Dis (2004) 1.40
Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis (2002) 1.38
Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology (2005) 1.37
Association between HLA-DR2 and production of tumour necrosis factor alpha and interleukin 1 by mononuclear cells activated by lipopolysaccharide. Scand J Immunol (1988) 1.37
Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy (1985) 1.37
Effect of cyclosporin A on human neutrophil and monocyte function. Scand J Immunol (1985) 1.35
Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection. Clin Exp Immunol (2000) 1.32
1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. Cytokine (1992) 1.29
Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis (2008) 1.28
Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood (1998) 1.27
Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis (2007) 1.27
Interleukin 6 primes human neutrophil and monocyte oxidative burst response. Immunol Lett (1989) 1.26
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis (2006) 1.25
Cognitive-behavioural therapies and exercise programmes for patients with fibromyalgia: state of the art and future directions. Ann Rheum Dis (2006) 1.25
DAS remission cut points. Clin Exp Rheumatol (2006) 1.23
Auto-antibodies to tumour necrosis factor alpha in healthy humans and patients with inflammatory diseases and gram-negative bacterial infections. Scand J Immunol (1989) 1.23
Inhibition of production and function of interleukin-6 by 1,25-dihydroxyvitamin D3. Immunol Lett (1991) 1.19
Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann Rheum Dis (2005) 1.18
Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment. Arthritis Care Res (Hoboken) (2011) 1.17
Bioactive and inactive forms of tumor necrosis factor-alpha in spinal fluid from patients with meningitis. J Infect Dis (1991) 1.17
Validity of histopathological grading of articular cartilage from osteoarthritic knee joints. Ann Rheum Dis (1999) 1.16
Interleukin-1-like activities in synovial fluids of patients with rheumatoid arthritis and traumatic synovitis. Rheumatol Int (1985) 1.16
Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res (Hoboken) (2010) 1.15
MADS-box genes active in developing pollen cones of Norway spruce (Picea abies) are homologous to the B-class floral homeotic genes in angiosperms. Dev Genet (1999) 1.15
IgG autoantibodies against interleukin 1 alpha in sera of normal individuals. Scand J Immunol (1989) 1.14
Low concentrations of interleukin-1 stimulate and high concentrations inhibit insulin release from isolated rat islets of Langerhans. Acta Endocrinol (Copenh) (1986) 1.14
Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol (2000) 1.14
Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. Rheumatology (Oxford) (2002) 1.12
High-avidity autoantibodies to cytokines. Immunol Today (1998) 1.12
Inhibition of PTH secretion by interleukin-1 beta in bovine parathyroid glands in vitro is associated with an up-regulation of the calcium-sensing receptor mRNA. Biochem Biophys Res Commun (1997) 1.12
Type I interferons might form the link between Toll-like receptor (TLR) 3/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA). Ann Rheum Dis (2008) 1.10
Conservation of gene structure and activity in the regulation of reproductive organ development of conifers and angiosperms. Plant J (1998) 1.09
[Chronic fatigue syndrome--a controlled cross-sectional study]. Ugeskr Laeger (1994) 1.08
Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro. Endocrinology (1990) 1.08
Appearance self-esteem in systemic sclerosis--subjective experience of skin deformity and its relationship with physician-assessed skin involvement, disease status and psychological variables. Rheumatology (Oxford) (2007) 1.08
Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis. Rheumatology (Oxford) (2002) 1.07
Histologic/histochemical grading system for osteoarthritic articular cartilage: reproducibility and validity. Arthritis Rheum (1997) 1.06
Interleukin-13 prevents autoimmune diabetes in NOD mice. Diabetes (1999) 1.06
Specific binding of interleukin 1 (IL-1) beta and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I. Cytokine (1993) 1.04
Islet cytotoxicity of interleukin 1. Influence of culture conditions and islet donor characteristics. Diabetes (1987) 1.04
Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur Neurol (2004) 1.03
Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. Scand J Rheumatol (2004) 1.03
Studies on the active site of human leukocytic pyrogen. Inflammation (1982) 1.02
Effect of physical exercise on in vitro production of interleukin 1, interleukin 6, tumour necrosis factor-alpha, interleukin 2 and interferon-gamma. Int J Sports Med (1991) 1.02
1,25-Dihydroxyvitamin D3 as a natural regulator of human immune functions. J Investig Dermatol Symp Proc (1996) 1.02
Mechanisms of pancreatic islet cell destruction. Dose-dependent cytotoxic effect of soluble blood mononuclear cell mediators on isolated islets of Langerhans. Allergy (1986) 1.02
Proliferation induced by Plasmodium falciparum antigen and interleukin-2 production by lymphocytes isolated from malaria-immune individuals. Infect Immun (1986) 1.02
Right ventricle Tei-index: a tool to increase the accuracy of non-invasive detection of pulmonary arterial hypertension in connective tissue diseases. Eur J Echocardiogr (2006) 1.01
Consensus Dutch health assessment questionnaire. Ann Rheum Dis (2007) 1.01
Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis (2007) 1.01